This Article Full Text Full Text (PDF) All Versions of this Article: 106/24/3120    most recent 01.CIR.0000039341.57809.1Ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fiorucci, S. Articles by Minuz, P. Search for Related Content PubMed PubMed Citation Articles by Fiorucci, S. Articles by Minuz, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID ISOSORBIDE DINITRATE NITRIC OXIDE Related Collections Cardiovascular Pharmacology

(Circulation. 2002;106:3120.)
© 2002 American Heart Association, Inc.

Basic Science Reports

NCX-4016 (NO-Aspirin) Inhibits Lipopolysaccharide-Induced Tissue Factor Expression In Vivo

Role of Nitric Oxide

Stefano Fiorucci, MD; Andrea Mencarelli, BS; Alessandra Meneguzzi, BS; Alessandro Lechi, MD; Antonio Morelli, MD; Piero del Soldato, PhD; Pietro Minuz, MD

From Dipartimento di Medicina Clinica e Sperimentale, Clinica di Gastroenterologia ed Epatologia, Università degli Studi di Perugia, Italy (S.F., A. Mencarelli, A. Morelli); Dipartimento di Scienze Biomediche e Chirurgiche, Università di Verona, Italy (A. Meneguzzi, A.L., P.M.); NicOx S.A., Sophia Antipolis, France (P.d.S.); and New York Medical College, Valhalla, NY (P.d.S.).

Correspondence to Dr Pietro Minuz, Medicina Interna C, Policlinico GB Rossi, Piazzale LA Scuro 10, 37134 Verona, Italy. E-mail pietro.minuz{at}univr.it

Background— NCX-4016 is an acetylsalicylic acid (ASA) derivative containing a nitric oxide–releasing moiety. Compared with ASA, NCX-4016 has a broader spectrum of antithrombotic and antiinflammatory activities. We hypothesized that NCX-4016 might inhibit in vivo lipopolysaccharide (LPS)-induced expression of tissue factor (TF).

Methods and Results— Rats were administered 90 mg/kg NCX-4016 orally for 5 days. Placebo, 50 mg/kg ASA, and 80 mg/kg isosorbide-5-mononitrate (ISMN) were used in control groups. On day 5, rats were injected intraperitoneally with 100 µg/kg LPS and killed 6 hours later. The expression of TF in monocytes was measured by flow cytometry and Western blot analysis. Reverse transcriptase–polymerase chain reaction was performed to assess expression of TF and cyclooxygenase-2 (COX-2) genes. Plasma concentrations of interleukin-1ß and tumor necrosis factor- were measured. Urine samples were collected to evaluate the excretion of the thromboxane metabolite 11-dehydro-thromboxane (TX)B₂. Gastric mucosa was inspected. LPS injection was followed by synthesis TF and COX-2 mRNAs in circulating monocytes, which were blunted by NCX-4016 but not by ASA or ISMN. Both NCX-4016 and ISMN reduced TF expression on surface of circulating monocyte. LPS increased the excretion 11-dehydro-TXB₂, and this was prevented by NCX-4016 and ASA. Unlike ASA, NCX-4016 reduced plasma interleukin-1ß and tumor necrosis factor-. In addition, NCX-4016 almost completely prevented mucosal damage, whereas ASA increased the extension of gastric lesions in LPS-injected rats.

Conclusions— NCX-4016 prevents monocyte TF expression; this is accompanied by inhibition of TX and cytokine biosynthesis. These additive effects of nitric oxide release and COX inhibition may help explain efficacy and tolerability of NCX-4016.

Key Words: thromboxane • aspirin • platelets • nitric oxide

This article has been cited by other articles:

				H. Obata, Y. Sakai, S. Ohnishi, S. Takeshita, H. Mori, M. Kodama, K. Kangawa, Y. Aizawa, and N. Nagaya Single Injection of a Sustained-release Prostacyclin Analog Improves Pulmonary Hypertension in Rats Am. J. Respir. Crit. Care Med., January 15, 2008; 177(2): 195 - 201. [Abstract] [Full Text] [PDF]

				C. Emanueli, S. Van Linthout, M. B. Salis, A. Monopoli, P. Del Soldato, E. Ongini, and P. Madeddu Nitric Oxide-Releasing Aspirin Derivative, NCX 4016, Promotes Reparative Angiogenesis and Prevents Apoptosis and Oxidative Stress in a Mouse Model of Peripheral Ischemia Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 2082 - 2087. [Abstract] [Full Text] [PDF]

				S. Fiorucci, A. Mencarelli, A. Meneguzzi, A. Lechi, B. Renga, P. del Soldato, A. Morelli, and P. Minuz Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans J. Am. Coll. Cardiol., August 4, 2004; 44(3): 635 - 641. [Abstract] [Full Text] [PDF]

				S. Fiorucci, A. Mencarelli, E. Distrutti, M. Baldoni, P. del Soldato, and A. Morelli Nitric Oxide Regulates Immune Cell Bioenergetic: A Mechanism to Understand Immunomodulatory Functions of Nitric Oxide-Releasing Anti-Inflammatory Drugs J. Immunol., July 15, 2004; 173(2): 874 - 882. [Abstract] [Full Text] [PDF]

				E. Ongini, F. Impagnatiello, A. Bonazzi, M. Guzzetta, M. Govoni, A. Monopoli, P. Del Soldato, and L. J. Ignarro Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties PNAS, June 1, 2004; 101(22): 8497 - 8502. [Abstract] [Full Text] [PDF]

				S. Fiorucci, E. Distrutti, A. Mencarelli, G. Rizzo, A. R. D. Lorenzo, M. Baldoni, P. del Soldato, A. Morelli, and J. L. Wallace Cooperation between Aspirin-Triggered Lipoxin and Nitric Oxide (NO) Mediates Antiadhesive Properties of 2-(Acetyloxy)benzoic Acid 3-(Nitrooxymethyl)phenyl Ester (NCX-4016) (NO-Aspirin) on Neutrophil-Endothelial Cell Adherence J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1174 - 1182. [Abstract] [Full Text] [PDF]

				J. L. Wallace, M. N. Muscara, G. de Nucci, S. Zamuner, G. Cirino, P. del Soldato, and E. Ongini Gastric Tolerability and Prolonged Prostaglandin Inhibition in the Brain with a Nitric Oxide-Releasing Flurbiprofen Derivative, NCX-2216 [3-[4-(2-Fluoro-{alpha}-methyl-[1,1'-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester] J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 626 - 633. [Abstract] [Full Text] [PDF]

				J. L. Wallace, S. R. Zamuner, W. McKnight, M. Dicay, A. Mencarelli, P. del Soldato, and S. Fiorucci Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation Am J Physiol Gastrointest Liver Physiol, January 1, 2004; 286(1): G76 - G81. [Abstract] [Full Text] [PDF]

				J. L. Williams, N. Nath, J. Chen, T. R. Hundley, J. Gao, L. Kopelovich, K. Kashfi, and B. Rigas Growth Inhibition of Human Colon Cancer Cells by Nitric Oxide (NO)-Donating Aspirin Is Associated with Cyclooxygenase-2 Induction and {beta}-Catenin/T-Cell Factor Signaling, Nuclear Factor-{kappa}B, and NO Synthase 2 Inhibition: Implications for Chemoprevention Cancer Res., November 15, 2003; 63(22): 7613 - 7618. [Abstract] [Full Text] [PDF]

				S. Fiorucci, L. Santucci, J. L. Wallace, M. Sardina, M. Romano, P. del Soldato, and A. Morelli Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa PNAS, September 16, 2003; 100(19): 10937 - 10941. [Abstract] [Full Text] [PDF]